| Budget Amount *help |
¥5,200,000 (Direct Cost: ¥4,000,000、Indirect Cost: ¥1,200,000)
Fiscal Year 2015: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
Fiscal Year 2014: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2013: ¥2,990,000 (Direct Cost: ¥2,300,000、Indirect Cost: ¥690,000)
|
|---|
| Outline of Final Research Achievements |
We have previously reported that human induced pluripotent stem (iPS) cell technology is useful for disease specific in vivo cell model and drug screening. Since many kinds of ion channels express in the cardiomyocytes, it is desirable to investigate the effects of anti-arrhythmic drugs on electrophysiological properties in native cardiomyocytes.
In this study, first, we have succeeded in the induction of human iPS cell derived cardiomyocytes. QT PCR analyses revealed the expression of several ion channels such as SCN5A、CACNA1G、HCN4 in undifferentiated human iPS cells. Second, we investigated the effects of Bepridil on ion channel expression in human iPS cell derived cardiomyocytes. Bepridil dose dependently increased the expression of SCN5A, CACNA1, CACNA1G, HCN4. These results indicated that Bepridil may modulate ion channel expression in cardiomyocytes, resulting in the chronic effects of Bepridil in addition to the acute direct effect on the ion channels.
|
